SEC Form 4

Ш

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] <u>NEEL BRIAN</u>						2. Issuer Name and Ticker or Trading Symbol <u>MARAVAI LIFESCIENCES HOLDINGS</u> , <u>INC.</u> [MRVI]									all applicab Director	le)	Person(s) to Issuer 10% Ow Other (s		-
(Last) (First) (Middle) C/O MARAVAI LIFESCIENCES HOLDINGS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 10/31/2022									below)	,		Other (specify below) emarks	
10770 WATERIDGE CIRCLE, SUITE 200						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street) SAN DIEGO CA 92121															Form file	d by More	than C	one Reportin	g Person
(City)	(State)	(Zi	p)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date					Date E Month/Day/Year) it		2A. Deemed Execution Date, if any (Month/Day/Year)					ies Acquired (A) or Of (D) (Instr. 3, 4 an			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount		(A) or (D)	Price	(Instr. 3 an				(1130.4)
Class A Common Stock 10/3						31/2022			A ⁽¹⁾	v	329		Α	\$14.11	18,785			D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Expirat (Month)	ion Da		Secu Deri	itle and A urities Un vative Se tr. 3 and 4	derlying curity)	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti	s Ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	(A)	(A) (D) Exercis		able	Expiration Date Title		•	Amount or Number of Shares		(Instr. 4)					

Explanation of Responses:

1. The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 329 shares of Class A Common Stock was exempt pursuant to Rule 16b-3.

Remarks:

/s/ Kurt Oreshack, by power of attorney for Brian Neel

** Signature of Reporting Person

<u>10/31/2022</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.